Meta analysis on cinepazide maleate in treatment of diabetic peripheral neuropath

HUANG Qiu-ming; TU Xue-song; YAN Qiong; SHI Chuan-lin

doi:10.3969/j.issn.1006-0111.2012.02.016

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To assess the efficacy and safety of Cinepazide Maleate(CPZD) in the treatment of diabetic peripheral neuropath(DPN),with evidence-based medicine methods. Methods By retrieving related database,such as Medline(1977~2011.11), CNKI(1994~2011.11), WANFANG(1989~2011.11), VIP(1989~2011.11), the randomized controlled trials on DPN treatment by CPZD were included and analyzed according to the inclusion criteria.Meta analysis was used in this study. Results There were 982 cases of 11 trials were included in the analysis, the methodological quality of all studies included were rated as C-class. Meta-analysis showed that: 1Efficient: CPZD group was significantly higher than control group[OR and 95% CI=4.33 (2.45,7.66)]2Improvement of neurological function: The combined effect size of common peroneal nerve(CPN) SNCV and MNCV, median nerve(MN) SNCV and MNCV were as follows, CPN-SNCV:WMD=2.52,95%CI(1.92,3.13);CPN-MNCV:WMD=3.07,95%CI(1.59,4.55);MN-MNCV: WMD=3.97,95%CI(1.87,6.07);MN-SNCV:WMD=2.94,95%CI(1.43,4.46), the above-mentioned value were significantly higher than control group. 3Adverse reactions were less, mainly showed mild headache, dizziness, gastrointestinal discomfort. Conclusions Cinepazide Maleate might have positive effect on DPN. However,the evidence was not strong enough due to the general low methodological quality.A reliable conclusion about the effects of CPZD on DPN could not be summarized at the moment. Further large high-quality randomized controlled trials should be done.

Meta analysis on cinepazide maleate in treatment of diabetic peripheral neuropath

1. Pharmacy of Department, Xiaogan Central Hospital, Xiaogan 432000, China

2. Jilin Medical College, 2009 pharmacy student, Jilin 132013, China

Received Date: 2011-12-22

Rev Recd Date: 2012-02-27

Key words:

Abstract: Objective To assess the efficacy and safety of Cinepazide Maleate(CPZD) in the treatment of diabetic peripheral neuropath(DPN),with evidence-based medicine methods. Methods By retrieving related database,such as Medline(1977~2011.11), CNKI(1994~2011.11), WANFANG(1989~2011.11), VIP(1989~2011.11), the randomized controlled trials on DPN treatment by CPZD were included and analyzed according to the inclusion criteria.Meta analysis was used in this study. Results There were 982 cases of 11 trials were included in the analysis, the methodological quality of all studies included were rated as C-class. Meta-analysis showed that: 1Efficient: CPZD group was significantly higher than control group[OR and 95% CI=4.33 (2.45,7.66)]2Improvement of neurological function: The combined effect size of common peroneal nerve(CPN) SNCV and MNCV, median nerve(MN) SNCV and MNCV were as follows, CPN-SNCV:WMD=2.52,95%CI(1.92,3.13);CPN-MNCV:WMD=3.07,95%CI(1.59,4.55);MN-MNCV: WMD=3.97,95%CI(1.87,6.07);MN-SNCV:WMD=2.94,95%CI(1.43,4.46), the above-mentioned value were significantly higher than control group. 3Adverse reactions were less, mainly showed mild headache, dizziness, gastrointestinal discomfort. Conclusions Cinepazide Maleate might have positive effect on DPN. However,the evidence was not strong enough due to the general low methodological quality.A reliable conclusion about the effects of CPZD on DPN could not be summarized at the moment. Further large high-quality randomized controlled trials should be done.

HTML

Reference (19)

[1]	Kashyap AS,Anand KP, Kashyap S, et al. Peripheral neuropathy[J]. Lancet, 2004, 364(9446):1664.
[2]	张丽,黄道飞,刘胜.心脑血管新药马来酸桂哌齐特药理及临床综述[J].中国临床医药研究杂志,2002, 7(6):7002.
[3]	中华医学会糖尿病学分会.中国2型糖尿病防治指南(2007年版)[J].中华内分泌代谢杂志,2008,24(2):增录2a-3.
[4]	Laporte JR, CapellàD, Juan J. Agranulocytosis induced by cinepazide[J]. Eur J Clin Pharmacol, 1990, 38(4): 387.
[5]	李庆,叶真,倪海祥.糖尿病周围神经病变的临床评估和诊断进展[J]. 浙江临床医学,2008,10(10):1388.
[6]	陈国军,张燕柳,于永娜,等.马来酸桂哌齐特与甲钴胺联合治疗糖尿病周围神经病变观察[J].首都医药,2009,5(10):57.
[7]	井爱芬,尹逊莲.马来酸桂哌齐特注射液治疗糖尿病周围血管神经病变70 例[J].中国民间疗法,2004,12(3):53.
[8]	雷涛,张秀珍.甲钴胺与马来酸桂哌齐特联合治疗糖尿病下肢神经病变的疗效观察[J].中国康复医学杂志,2006,21(6):552.
[9]	李万甫,粟爽.马来酸桂哌齐特注射液治疗糖尿病周围神经病变疗效观察[J].保健医学研究与实践,2007,4(1):36.
[10]	李卫红.马来酸桂哌齐特联合甲钴胺治疗糖尿病周围神经病变的临床观察[J].中国药物与临床,2009,9(7):636.
[11]	吕彩莲,王翠芬.银杏达莫注射液治疗糖尿病周围神经病变的疗效观察[J].实用医技杂志,2011,18(6):622.
[12]	王红梅.马来酸桂哌齐特治疗糖尿病性神经病变的临床观察[J].临床和实验医学杂志,200,6(2):106.
[13]	向超.马来酸桂哌齐特联合甲钴胺治疗糖尿病周围神经病变100 例的疗效观察[J].中国现代药物应用,2011,5(4):116.
[14]	张敏,张翠云,肖红,等.马来酸桂哌齐特对糖尿病周围神经病变的疗效评价[J].中国误诊学杂志,2011,11(27):6585.
[15]	张秀坤,侯英,徐明艳,等.马来酸桂哌齐特与B 族维生素联合治疗糖尿病周围神经病变疗效观察[J].黑龙江医学,2011,35(2):128.
[16]	郑建勋.马来酸桂哌齐特治疗糖尿病周围神经病变疗效分析[J].中国社区医师:医学专业,2011,13(20):84.
[17]	张晓霞,韩培云.马来酸桂哌齐特的药理作用及临床应用研究[J].中国药房, 2007, 18(26): 2060.
[18]	白玉国,张爱琴,郑清敏,等.桂哌齐特注射液不良反应回顾性分析[J].药物流行病学杂志, 2008,17(3): 174.
[19]	易湛苗,刘芳,张俊,等.桂哌齐特致血液系统不良反应的回顾与分析[J].药物不良反应杂志, 2010,12(4):251.

Message Board

Meta analysis on cinepazide maleate in treatment of diabetic peripheral neuropath

doi: 10.3969/j.issn.1006-0111.2012.02.016

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views